SRPT logo

SRPT Sarepta Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$17.58
-0.24 (-1.35%)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutati…

Market Cap: $1.86Bwww.sarepta.com

Price

No data yet.

Social Signal Score

43
5d
—
30d
40
6 mentions
—
60d
42
7 mentions
—
90d
46
10 mentions
—
news: 10

Analyst Ratings

55 analysts
Buyconsensus
Strong Buy 0Buy 31Hold 18Sell 6Strong Sell 0
Avg price target$21+19.5%
Low $17Median $19.5High $27
Current Consensus

Revenue

$381.35M+6934.70%
$5.42M$251.90M$498.38M$744.86M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-4.89
$-6.56–$-1.94
9 analysts
FY2026
$3.08
$2.26–$4.14
6 analysts
FY2027
$0.34-89% YoY
$0.08–$0.70
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael E. Severino
Sector
Healthcare
Industry
Biotechnology
Employees
835
Beta
0.20
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
0.02
www.sarepta.com